Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neuropathix Inc
(OP:
NPTX
)
N/A
UNCHANGED
Last Price
Updated: 12:23 PM EDT, Oct 19, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0003
Today's Range
N/A - N/A
52wk Range
0.0003 - 0.0003
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
March 14, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Cannabis
Exposures
Cannabis
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
May 25, 2022
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic...
From
Neuropathix, Inc.
Via
AccessWire
Exposures
COVID-19
Performance
More News
Read More
Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022
May 19, 2022
Via
Benzinga
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
April 13, 2022
From
Neuropathix, Inc.
Via
AccessWire
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
April 06, 2022
From
Neuropathix, Inc.
Via
AccessWire
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 25, 2022
From
Neuropathix, Inc.
Via
AccessWire
Topics
Cannabis
Derivatives
Intellectual Property
Exposures
Cannabis
Derivatives
Intellectual Property
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
January 18, 2022
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
November 17, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
September 28, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
August 24, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
August 12, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
July 20, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit